CYP1A2 – a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients

BACKGROUND: Endocrine resistance is a major obstacle to optimal treatment effect in breast cancer. Some genetic markers have been proposed to predict response to aromatase inhibitors (AIs) but the data is insufficient. The aim of the study was to find new genetic treatment predictive markers of AIs....

Descripción completa

Detalles Bibliográficos
Autores principales: Simonsson, Maria, Veerla, Srinivas, Markkula, Andrea, Rose, Carsten, Ingvar, Christian, Jernström, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815192/
https://www.ncbi.nlm.nih.gov/pubmed/27029552
http://dx.doi.org/10.1186/s12885-016-2284-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815192/
https://www.ncbi.nlm.nih.gov/pubmed/27029552
http://dx.doi.org/10.1186/s12885-016-2284-3

Ejemplares similares